Omeros Corporation Receives Commitment of Over $4M from NIDA for Further Development of the Company’s Program to Treat Cocaine Use Disorder

Omeros Corporation announced that it has received a funding commitment from the National Institute on Drug Abuse (NIDA) for the upcoming year in the amount of $4.02M for clinical development of OMS527, to treat cocaine use disorder (CUD) by reducing or eliminating craving and relapse in patients with CUD. This grant will fund the Phase 1b clinical trial in patients with CUD to assess OMS527 safety and efficacy.